Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

(2018) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor

(2018) R Wu et al.   Blood Cancer Journal

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

(2017) Peter Hollander et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients

(2017) Jun Chen et al.   OncoTargets and Therapy

Core needle biopsies for the diagnosis of diffuse large B-cell lymphoma – a great concern for research

(2016) Maysaa Abdulla et al.   ACTA ONCOLOGICA

Nivolumab in the Treatment of Hodgkin Lymphoma

(2016) Stephen M. Ansell   CLINICAL CANCER RESEARCH

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel treatment concepts in Hodgkin lymphoma

(2016) I. Glimelius et al.   JOURNAL OF INTERNAL MEDICINE

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and its ligands are important immune checkpoints in cancer

(2016) Yinan Dong et al.   Oncotarget

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

(2016) S. Vardhana et al.   HAEMATOLOGICA

5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers

(2016) Lauren Van Der Kraak et al.   Journal for ImmunoTherapy of Cancer

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

(2015) B Paiva et al.   LEUKEMIA

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy

(2014) Simone Muenst et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

Influence of Chemotherapy onEGFRMutation Status Among Patients With Non–Small-Cell Lung Cancer

(2012) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology